{"name":"Spirogen","slug":"spirogen","ticker":"","exchange":"","domain":"","description":"Spirogen is a biotechnology company focused on the development of potent and selective drug conjugates for the treatment of cancer. The company's lead program, SG2000, has been discontinued, indicating a shift in its research focus or strategic direction.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxONVVKQzM1d1hTbDlZNWJ0RWozLTBycWlHd1ZPTDd4aFFnQXR6SjdiTm5fRmN6WEo2QTVZR2RxcUw4N0tHTFA2UjJ0REFnU2lJS3U3SktNa2phZEtleGpFYTFkSmpCTEtTRGRWNVpwNHB0bEs1V3VxQ0UzM0l1aTNyRlJsZFl2MUE4?oc=5","date":"2022-10-20","type":"pipeline","source":"kcl.ac.uk","summary":"King's biotech spinout re-launches with new name and $68 million funding - kcl.ac.uk","headline":"King's biotech spinout re-launches with new name and $68 million funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQMG02cENWeTVjVWhvMjIxeXhzOUJOaWFleGRQNGRodE4wZmpMeFQyRzljNGJwQ3BsNEtGVHVORWlXQ3Y5a0dWbUktTEJIQjlRd3FfV1hCeVMzNTlKVEZlcW5VTUpSYW9VXzgyQUhaajFpTU1DWDltZkxSOFBNM1A2RnZhcUZCTWVxQ3U4em9wZlZwRjgtMkY4Rl81TU9VcEY4czVrUGtlUWlJWTR6WGlzVzdMOFcxRl9OVzlpQQ?oc=5","date":"2022-09-28","type":"pipeline","source":"Fierce Biotech","summary":"Pheon nabs $68M to ready clinical launch based on ADC-featured pipeline - Fierce Biotech","headline":"Pheon nabs $68M to ready clinical launch based on ADC-featured pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQU1lKZUtRRXdJb1dHX29xakNKeTdVZFJwMVExRzRmenlXcWtiQXVfMzBicnF0UHdJX0JCbzlQSFBtZGR1WVJTbUZ0N0R3ajRmLUt1OGdXZ1NTTGE5TmNnZ2dlUVJfcWRqVXctNmJvNWFVMmVsa0pKaldBZlBCUVpRVGIxNGxzR2UxakI0TXBoSzV4Q0gyazA5VDhR?oc=5","date":"2013-10-28","type":"pipeline","source":"Hospital Pharmacy Europe","summary":"Cancer drugs company sold for £124m - Hospital Pharmacy Europe","headline":"Cancer drugs company sold for £124m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNdlpMNFNFeE4tak80RVZFaE9TaWhWNlY0bDZrZ1o1NjByQUNxcmdDT0ItWk15WElPUjNFSUszQlh1dzBPaHJBN3hVRVJtYVNVd3RGck5rVVNZQ1ctYVd5R1FmT3EwWVJSVVVabkdZbVB5SHNRMnBLZzMydjd0UHRnZzlKcGhiandlWmdtR1cybkRYZE56MWVIZDhKbUk2Z0lFZzg5YktjY2FISDd6OWdkd1cwVGV0ZmVULXhHSVlZbmVZSE00?oc=5","date":"2013-10-15","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability - AstraZeneca","headline":"AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capabili","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQQzhsVlpwSXBPS0Z3WVRjbGlrQUxWQjlfWldjRFRERTU1UktsR2FPM05sM2IydHpGUjBZUnhfZm05cExVaWtGZmFFdDVwLUNJRFZDNnRWMjFwdkJRaDZfcnpPZm9EWlRFQjRjWFZwaHV3MnQ3aXZFZkhITTd6aUJGRVBjaGE1bFEyaVg3c0lVc0J5dUlULTQ3bldJU1Y2bk1wYks3U0lkT05KUzEtXzFvUVdOdEh4bXVULVFPMVZvZVFPb0g4UWgySkFjeWtxeWdQLVlfb2d0NXZZMktQZ0J6b2FwN2Y1T1FaeHpR?oc=5","date":"2013-03-12","type":"pipeline","source":"News-Medical","summary":"Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen - News-Medical","headline":"Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOaEpBdGdTci10X2ozUlh1Zmk5Wi1wdkdDX1Q2NGpLSXBjMERaY3hLT2tHV3NqTElFZmVfa3lGU0RYYmptRXkxaHhxRlgxM0hnTDJWbmVqaWtLNG5zYlBFbHpHd240ejhkbC14NmFfM19aMEVWMVRid0xyb1lOQW05WWxnODdrUGtjRkJQMlhmbVhYSlZ4bkhoelJKR2ZycHRwbWtpQkRaNVRtUk81T0kxeERLX3VLamNWLVU4Uk1FcDRVZ0d0M2p2cw?oc=5","date":"2009-10-08","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights - Genetic Engineering and Biotechnology News","headline":"Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}